Prevalence of Overweight and Obesity in the Era of CFTR Modulators in Patients with Cystic Fibrosis
Nutrients · 2026
DOI: 10.3390/nu18050755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2026. Verfasst von Anam Bashir und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology & Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Overweight, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Cystic fibrosis (CF) is a genetic disorder historically associated with malnutrition. The advent of CF transmembrane conductance regulator (CFTR) modulators and improved pulmonary outcomes have coincided with increased body mass index (BMI). This study aims to evaluate the prevalence of overweight/obesity among children with cystic fibrosis and associated comorbidities.
Methods
A retrospective chart review assessed patients with CF (2–23 years of age). Data collected included demographics, CF genotype, anthropometric measurements, pancreatic function, medication history, and any comorbid diagnoses. BMI categories were defined as: underweight (95th percentile).
Results
Among 243 patients (mean age 10.4 years, 53% male), 4 (1.6%) were malnourished, 192 (79%) had normal weight, and 47 (19.3%) were overweight (OW)/obese (26 (10.7%) OW, and 21 (8.6%) were obese). OW/obese patients (mean age 11.3 years, 61.7% male) included 20 patients (42.5%) with two severe CF-related mutations, 21 (44%) with pancreatic insufficiency, and 40 (85.1%) receiving CFTR modulator treatment. Obstructive sleep apnea (OSA) was the most common comorbidity in OW/obese patients with CF, followed by impaired glucose intolerance and CF-related diabetes and hyperlipidemia; these associations did not reach statistical significance.
Conclusions
Overweight/obesity affects nearly one in five patients with CF, including those with severe genotype and pancreatic insufficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology & Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Division of Pulmonology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Division of Clinical Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Center for Microbial Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
ORCID-Profile: Xingmei Wang, Elizabeth Reid, Nikhil Pai
Zitieren
APA
Bashir, A., Kastl, M. B., Wang, X., Padula, L., Reid, E., Kofsky, R., Pai, N., & Mascarenhas, M. (2026). Prevalence of Overweight and Obesity in the Era of CFTR Modulators in Patients with Cystic Fibrosis. Nutrients. https://doi.org/10.3390/nu18050755
Vancouver
Bashir A, Kastl MB, Wang X, Padula L, Reid E, Kofsky R, et al. Prevalence of Overweight and Obesity in the Era of CFTR Modulators in Patients with Cystic Fibrosis. Nutrients. 2026. doi:10.3390/nu18050755
BibTeX
@article{Bashir2026,
author = {Bashir, Anam and Kastl, Mary Bridget and Wang, Xingmei and Padula, Laura and Reid, Elizabeth and Kofsky, Rachel and Pai, Nikhil and Mascarenhas, Maria},
title = {Prevalence of Overweight and Obesity in the Era of CFTR Modulators in Patients with Cystic Fibrosis},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18050755}
}
EUVIMED